Stock Scorecard
Stock Summary for Rigel Pharmaceuticals (RIGL) - $38.06 as of 7/31/2026 5:17:59 PM EST
Total Score
17 out of 30
Safety Score
53 out of 100
Currently on the following lists
None
Tim's Recommendation
Possible Buy
Growth List Algorithm Criteria for RIGL
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for RIGL
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for RIGL
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for RIGL
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for RIGL (53 out of 100)
| Stock Price Rating (Max of 10) | 8 |
| Historical Stock Price Rating (Max of 10) | 6 |
| Stock Price Trend (Max of 10) | 10 |
| Book Value (Max of 10) | 7 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 3 |
| Analyst Strong Buy Ratings (Max of 5) | 0 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 5 |
| Trading Volume (Max of 10) | 4 |
| Price to Earnings (Max of 10) | 10 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for RIGL
Financial Details for RIGL
Company Overview |
|
|---|---|
| Ticker | RIGL |
| Company Name | Rigel Pharmaceuticals |
| Country | USA |
| Description | Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat blood disorders, cancer, and rare immune diseases. The company is headquartered in South San Francisco, California. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 3/31/2026 |
| Next Earnings Date | 8/4/2026 |
Stock Price History |
|
| Last Day Price | 38.06 |
| Price 4 Years Ago | 15.00 |
| Last Day Price Updated | 7/31/2026 5:17:59 PM EST |
| Last Day Volume | 216,113 |
| Average Daily Volume | 387,244 |
| 52-Week High | 52.24 |
| 52-Week Low | 20.28 |
| Last Price to 52 Week Low | 87.67% |
Valuation Measures |
|
| Trailing PE | 2.02 |
| Industry PE | 35.62 |
| Sector PE | 68.70 |
| 5-Year Average PE | 19.88 |
| Free Cash Flow Ratio | 28.83 |
| Industry Free Cash Flow Ratio | 30.19 |
| Sector Free Cash Flow Ratio | 35.90 |
| Current Ratio Most Recent Quarter | 2.62 |
| Total Cash Per Share | 1.32 |
| Book Value Per Share Most Recent Quarter | 21.64 |
| Price to Book Ratio | 1.78 |
| Industry Price to Book Ratio | 11.41 |
| Sector Price to Book Ratio | 22.92 |
| Price to Sales Ratio Twelve Trailing Months | 2.41 |
| Industry Price to Sales Ratio Twelve Trailing Months | 11.04 |
| Sector Price to Sales Ratio Twelve Trailing Months | 24.38 |
| Analyst Buy Ratings | 3 |
| Analyst Strong Buy Ratings | 0 |
Share Statistics |
|
| Total Shares Outstanding | 18,502,100 |
| Market Capitalization | 704,189,926 |
| Institutional Ownership | 93.78% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 1.33% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | -30.20% |
| Annual Earnings Growth | 1,999.08% |
| Reported EPS 12 Trailing Months | 19.29 |
| Reported EPS Past Year | 0.44 |
| Reported EPS Prior Year | 6.49 |
| Net Income Twelve Trailing Months | 364,232,000 |
| Net Income Past Year | 367,024,000 |
| Net Income Prior Year | 17,485,000 |
| Quarterly Revenue Growth YOY | 10.30% |
| 5-Year Revenue Growth | 22.06% |
| Operating Margin Twelve Trailing Months | 20.20% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 24,411,000 |
| Total Cash Past Year | 40,580,000 |
| Total Cash Prior Year | 56,746,000 |
| Net Cash Position Most Recent Quarter | 9,420,000 |
| Net Cash Position Past Year | 18,098,000 |
| Long Term Debt Past Year | 22,482,000 |
| Long Term Debt Prior Year | 52,408,000 |
| Total Debt Most Recent Quarter | 14,991,000 |
| Equity to Debt Ratio Past Year | 0.95 |
| Equity to Debt Ratio Most Recent Quarter | 0.96 |
| Total Stockholder Equity Past Year | 391,480,000 |
| Total Stockholder Equity Prior Year | 3,288,000 |
| Total Stockholder Equity Most Recent Quarter | 399,897,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | 79,249,000 |
| Free Cash Flow Per Share Twelve Trailing Months | 4.28 |
| Free Cash Flow Past Year | 75,655,000 |
| Free Cash Flow Prior Year | 31,075,000 |
Options |
|
| Put/Call Ratio | 0.05 |
| Has Options | Options Chain |
| Liquidity Rating | None |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.50 |
| MACD Signal | 1.10 |
| 20-Day Bollinger Lower Band | 22.25 |
| 20-Day Bollinger Middle Band | 32.31 |
| 20-Day Bollinger Upper Band | 42.36 |
| Beta | 1.13 |
| RSI | 52.58 |
| 50-Day SMA | 35.11 |
| 150-Day SMA | 21.90 |
| 200-Day SMA | 19.63 |
System |
|
| Modified | 7/30/2026 6:54:51 AM EST |